Splash Beverage Group entered into an addendum to its exclusive global license for CannEpil to include veterinary applications. The amendment sets a 10% royalty on net revenue from veterinary uses and a 15% royalty for human applications, and extends certain deadlines under the original license. Management expects the broader scope and clarified economics to support expansion into new markets.

Agreement details:

  • Agreement type: Addendum to exclusive global license for CannEpil
  • Counterparty: Argent BioPharma
  • Signed / Effective: Jul 28 2026 / same
  • Reason: Broaden CannEpil market to veterinary use and refine royalties

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.